Published September 15, 2026 | Version v1

THE ROLE OF HYPERPROLACTINEMIA IN REPRODUCTIVE AND METABOLIC ENDOCRINE DISORDERS

  • 1. Worldly Knowledge Publishing Centre

Description

Hyperprolactinemia is an endocrine disorder characterized by persistently elevated serum prolactin concentrations and may result from physiological conditions, medications, hypothalamic-pituitary disease, or systemic disorders. The condition has important effects on reproductive, gonadal, metabolic, and neuroendocrine function. The aim of this study was to analyze the major pathophysiological mechanisms, clinical manifestations, diagnostic principles, and treatment strategies associated with hyperprolactinemia. A literature-based analytical approach was used to evaluate prolactin synthesis, dopamine-mediated inhibition, gonadotropin-releasing hormone suppression, pituitary adenomas, medication-induced hyperprolactinemia, and associated reproductive dysfunction. The analysis indicates that excessive prolactin inhibits hypothalamic GnRH secretion, leading to reduced luteinizing hormone and follicle-stimulating hormone release and subsequent hypogonadism. In women, this may cause menstrual disturbances, infertility, and galactorrhea, whereas men may develop reduced libido, erectile dysfunction, infertility, and decreased testosterone levels. Prolactinomas represent an important pathological cause, while dopamine antagonist medications are among the most common pharmacological causes. Accurate diagnosis requires confirmation of persistent prolactin elevation, exclusion of physiological and secondary causes, evaluation of thyroid and renal function, and pituitary imaging when indicated. Dopamine agonists remain the principal treatment in most symptomatic prolactinomas and can normalize prolactin secretion and reduce tumor size. Hyperprolactinemia should therefore be considered an important endocrine disorder with both reproductive and systemic consequences.

Files

413-417.pdf

Files (262.4 kB)

Name Size
md5:caab54b600683b6a0f2a31d88e270b8b
262.4 kB Preview Download

Additional details

References

  • 1.Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism. 2011;96(2):273–288.
  • 2.Скворцова, Л. А., Махмудов, Д. Э., Усманов, Д. Р., Адылходжаев, А. А., & Хегай, Л. Н. (2019). АСПЕКТЫ СПОРТИВНОЙ АДАПТОЛОГИИ ПРИ ИЗУЧЕНИИ ВИТАМИНА D 25 (OH) D У ФУТБОЛИСТОВ. In От фундаментальных знаний к тонкому владению скальпелем (pp. 51-54).
  • 3.Хегай, Л. Н., Скворцова, Л. А., Махмудов, Д. Э., Усманов, Д. Р., Муслимов, О. Я., & Адылходжаев, А. А. (2019). СОДЕРЖАНИЕ 25-OH-ВИТАМИНА D У ФУТБОЛИСТОВ В УСЛОВИЯХ СОЛНЕЧНОЙ РАДИАЦИИ УЗБЕКИСТАНА. In Actual Questions and Innovations in Science 2 (pp. 160-161).
  • 4.Mavlyanov, I., Parpiev, S., Sadikov, A., Kurganov, S., & Makhmudov, D. (2020). Relative features of the PPARA (Rs4253778), PPARGC1A (Rs8192678) and PPARG2 (Rs1801282) polymorphisms genes in athletes engaged in cyclic types of sports. European Journal of Molecular and Clinical Medicine, 7(2), 1860-1869.
  • 5.Пирназаров, М. М., Садиков, А. А., Махмудов, Д. Э., & Хегай, Л. Н. (2021). Магнитно-резонансная томографическая визуализация повреждений коленных суставов. Re-health journal, (1 (9)), 152-159.